Prelude Therapeutics (PRLD) EBITDA (2019 - 2026)

Prelude Therapeutics has reported EBITDA for 8 years, with the latest figure at -$14.2 million in Q1 2026.

• Quarterly EBITDA rose 59.03% year-over-year to -$14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.1 million (up 39.89% YoY) and the FY2025 annual result came in at -$104.6 million, up 25.16% from the prior year.
• EBITDA advanced to -$14.2 million in Q1 2026 per PRLD's latest filing, from -$17.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$14.2 million in Q1 2026 and troughed at -$37.4 million in Q4 2023.
• A 5-year average of -$30.3 million and a median of -$32.4 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2026: EBITDA plunged 37.88% in 2022, then soared 59.03% in 2026.
• Over 5 years, EBITDA stood at -$33.4 million in 2022, then declined by 11.96% to -$37.4 million in 2023, then gained by 9.49% to -$33.8 million in 2024, then surged by 48.72% to -$17.3 million in 2025, then rose by 18.28% to -$14.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$14.2 million, -$17.3 million, and -$20.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.